IP Library Granted Patent US 8,765,786
Granted Patent B2
US 8,765,786 · App. 14/137,895 · Granted Jul 1, 2014

1-substituted indazole derivative

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,765,786
App. No.
14/137,895
Granted
Jul 1, 2014
Kind
B2
Abstract

A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I), wherein A is CR 1E or a nitrogen atom, X—Y—Z is N—CO—NR 3A R 3B and the like, R 1A to R 1E are each independently a hydrogen atom and the like, R 2A to R 2D are each independently a hydrogen atom and the like, R 3A and R 3B are each independently an optionally-substituted C3-10 cycloalkyl and 15 the like, and n is 1 or 2 or a pharmaceutically acceptable salt thereof, which exhibits potent modulatory-effects on the activity of alpha-7 nicotinic acetylcholine receptor (alpha-7 nAChR).

Claims (8)

1. A compound selected from the group consisting of:

N-(trans-4-methoxycyclohexyl)-4-(5-methyl-1H-indazol-1-yl)piperidine-1-carboxamide; and 4-(5-cyclopropyl-1H-indazol-1-yl)-N-(trans-4-methoxycyclohexyl)piperidine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is N-(trans-4-methoxycyclohexyl)-4-(5-methyl-1H-indazol-1-yl)piperidine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is 4-(5-cyclopropyl-1H-indazol-1-yl)-N-(trans-4-methoxycyclohexyl)piperidine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

4. A method for treating CIAS (cognitive impairment associated with schizophrenia) comprising administering a therapeutically effective amount of a compound selected from the group consisting of:

N-(trans-4-methoxycyclohexyl)-4-(5-methyl-1H-indazol-1-yl)piperidine-1-carboxamide; and 4-(5-cyclopropyl-1H-indazol-1-yl)-N-(trans-4-methoxycyclohexyl)piperidine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

5. The method of claim 4 , wherein the compound is N-(trans-4-methoxycyclohexyl)-4-(5-methyl-1H-indazol-1-yl)piperidine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

6. The method of claim 4 , wherein the compound is 4-(5-cyclopropyl-1H-indazol-1-yl)-N-(trans-4-methoxycyclohexyl)piperidine-1-carboxamide, or a pharmaceutically acceptable salt thereof.

Assignments (4)
CHANGE OF NAME Recorded Nov 21, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 061972/0730 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 034017 FRAME 0931. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE. Recorded Nov 17, 2014
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 034274/0073 →
CHANGE OF NAME Recorded Oct 20, 2014
From: DAINIPPON SUMITOMO PHARMA CO., LTD.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 034017/0931 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2014
From: USUI, SHINYA; YAMAGUCHI, HIROKI; NAKAI, YOKO
To: DAINIPPON SUMITOMO PHARMA CO., LTD.
Reel/Frame 032220/0388 →